Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity

BACKGROUND: T cell checkpoint immunotherapies have shown promising results in the clinic, but most patients remain non-responsive. CD47-signal regulatory protein alpha (SIRPα) myeloid checkpoint blockade has shown early clinical activity in hematologic malignancies. However, CD47 expression on perip...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shih-Hsun, Dominik, Pawel K, Stanfield, Jessica, Ding, Sheng, Yang, Wenjing, Kurd, Nadia, Llewellyn, Ryan, Heyen, Jonathan, Wang, Carole, Melton, Zea, Van Blarcom, Thomas, Lindquist, Kevin C, Chaparro-Riggers, Javier, Salek-Ardakani, Shahram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488710/
https://www.ncbi.nlm.nih.gov/pubmed/34599020
http://dx.doi.org/10.1136/jitc-2021-003464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488710/
https://www.ncbi.nlm.nih.gov/pubmed/34599020
http://dx.doi.org/10.1136/jitc-2021-003464

Ejemplares similares